Cooley advised CStone Pharmaceuticals on its exclusive collaboration and license agreement with Blueprint Medicines to develop and commercialize its cancer therapy, avapritnib, in mainland China, Hong Kong, Macau and Taiwan.
Under the terms of the agreement, CStone will make an upfront payment of $40 million in cash to Blueprint. Blueprint is also eligible to receive approximately $346 million in potential milestone payments in addition to tiered percentage royalties.
CStone is a Shanghai and Suzhou-based innovative biopharmaceutical company devoted to the development of a new generation of innovative drugs.
Cooley advised with a team including Christina Zhang (Picture), Alison Freeman-Gleason and Bin Wang.
Law Firms: Cooley LLP;
Clients: CStone Pharmaceuticals;